Workflow
KHB(002022)
icon
Search documents
科华生物收盘下跌1.16%,最新市净率0.94,总市值30.60亿元
Sou Hu Cai Jing· 2025-05-28 08:56
Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents and medical testing instruments [1] - The latest financial report for Q1 2025 shows a revenue of 388 million yuan, a year-on-year decrease of 12.50%, and a net profit of -53.26 million yuan, a year-on-year decrease of 84.79% [1] - The company has a current market capitalization of 3.06 billion yuan and a price-to-book ratio of 0.94 [1] Group 2 - The company has received several honors, including the National Science and Technology Progress Award and recognition as a National High-tech Enterprise [1] - As of the latest report, five institutions hold shares in the company, with a total holding of 114.66 million shares valued at 649 million yuan [1] - The company's gross profit margin stands at 37.39% [1] Group 3 - The company's PE (TTM) is -4.60, while the industry average PE is 48.81 [2] - The company is compared to other firms in the industry, with varying PE ratios and market capitalizations [2] - The industry median price-to-book ratio is 2.40, while the company's is 0.94 [2]
科华生物收盘上涨1.00%,最新市净率0.95,总市值31.12亿元
Sou Hu Cai Jing· 2025-05-20 08:39
Group 1 - The core business of the company is the research, production, and sales of in vitro diagnostic reagents and medical testing instruments [1] - As of March 31, 2025, the number of shareholders is 42,590, a decrease of 1,756 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest financial report for Q1 2025 shows a revenue of 388 million yuan, a year-on-year decrease of 12.50%, and a net profit of -53,259,784.78 yuan, a year-on-year decrease of 84.79%, with a gross profit margin of 37.39% [1] Group 2 - The company's current price-to-earnings ratio (TTM) is -4.68, and the price-to-book ratio is 0.95, with a total market capitalization of 3.112 billion yuan [2] - The industry average price-to-earnings ratio is 49.51, while the industry median is 36.17, indicating that the company is significantly below industry averages [2] - The company has received various honors, including the National Science and Technology Progress Second Prize and recognition as a National High-tech Enterprise [1]
科华生物(002022) - 2024年度股东大会决议公告
2025-05-19 10:45
| 证券代码:002022 | 证券简称:科华生物 公告编号:2025-030 | | --- | --- | | 债券代码:128124 | 债券简称:科华转债 | 上海科华生物工程股份有限公司 2024年度股东大会决议公告 1、召开时间: (1)现场会议时间:2025年5月19日(星期一)下午14:30 (2)网络投票时间:2025年5月19日 其中,通过深圳证券交易所交易系统进行网络投票的具体时间为2025年5月 19日的交易时间,即9:15-9:25,9:30-11:30和13:00-15:00;通过深圳证券交易 所互联网投票系统投票的具体时间为2025年5月19日9:15-15:00期间的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 2、召开地点:上海市徐汇区钦州北路1189号公司会议室 3、召集人:公司董事会 4、主持人:董事长李明先生 5、召开方式:本次股东大会采用现场投票、网络投票相结合的方式召开 6、本次会 ...
科华生物(002022) - 北京市金杜(广州)律师事务所关于上海科华生物工程股份有限公司2024年度股东大会之法律意见书
2025-05-19 10:45
北京市金杜(广州)律师事务所 关于 上海科华生物工程股份有限公司 2024 年度股东大会 之法律意见书 致:上海科华生物工程股份有限公司 北京市金杜(广州)律师事务所(以下简称本所)接受上海科华生物工程股份 有限公司(以下简称公司)的委托,根据《中华人民共和国公司法》(以下简称《公 司法》)、《中华人民共和国证券法》(以下简称《证券法》)、中国证券监督管理委员 会《上市公司股东会规则》(2025 年修订)(以下简称《股东会规则》)等中华人民 共和国境内(以下简称中国境内,为本法律意见书之目的,不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾地区)现行有效的法律、行政法规、规章、 规范性文件和现行有效的公司章程有关的规定,指派本所律师出席了公司于 2025 年 5 月 19 日召开的 2024 年度股东大会(以下简称"本次股东大会"),并就本次股 东大会相关事项出具本法律意见书。 为出具本法律意见书,本所律师审查了公司提供的以下文件,包括但不限于: 1 1. 经公司 2024 年第一次临时股东大会审议通过的《上海科华生物工程股份 有限公司章程》(以下简称《公司章程》); 2. 公司于 2025 年 4 ...
医药生物行业周报:持续看好创新药领域
Guoyuan Securities· 2025-05-19 10:40
Investment Rating - The report maintains a positive outlook on the innovative drug sector within the healthcare industry [1]. Core Insights - The pharmaceutical sector outperformed the CSI 300 index slightly, with the Shenwan Pharmaceutical and Biological Index rising by 1.27% from May 12 to May 16, 2025, and by 2.48% year-to-date, ranking 11th among 31 Shenwan primary industry indices [1][12]. - The current valuation of the pharmaceutical sector stands at 26.80 times (TTM overall method, excluding negative values), with a premium of 141.06% compared to the CSI 300 index [15]. - The innovative drug segment is experiencing a pullback due to U.S. President Trump's announcement regarding drug price reductions, but the report suggests that the actual implementation of such policies will be challenging and will not significantly impact Chinese innovative drug companies' international expansion [3][20]. Summary by Sections 1. Market Review - The pharmaceutical sector's performance from May 12 to May 16, 2025, showed a 1.27% increase, outperforming the CSI 300 index by 0.15 percentage points [10]. - Year-to-date, the sector has increased by 2.48%, surpassing the CSI 300 index by 3.64 percentage points [12]. 2. Key Events - On May 12, 2025, President Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S., potentially lowering prices by 30% to 80% [19]. 3. Industry Perspective - The innovative drug sector is expected to continue as a key investment theme for 2025, with a focus on international expansion and emerging markets, particularly in companies like Kexing Pharmaceutical [4][21]. - The report highlights that the ongoing collection and procurement policies in various pharmaceutical fields are accelerating, with potential growth in segments like insulin and orthopedics [4][21].
5月12日医疗器械概念上涨1.19%,板块个股尚荣医疗、鹿得医疗涨幅居前
Sou Hu Cai Jing· 2025-05-12 10:29
Core Viewpoint - The medical device industry experienced a rise of 1.19% on May 12, with a net inflow of 172 million in capital, indicating positive investor sentiment towards the sector [1] Group 1: Market Performance - A total of 98 stocks in the medical device sector increased in value, while 20 stocks declined [1] - The top-performing stocks included: - Shangrong Medical (+10.0%) - Lude Medical (+7.78%) - Kaili Medical (+6.88%) - Aipeng Medical (+5.45%) - Shuoshi Biological (+5.0%) [1] Group 2: Capital Inflow - The net capital inflow for the top stocks was as follows: - Shangrong Medical: 4.8 million, 43.17% of net capital - Lude Medical: 1.99 million, 18.01% of net capital - Kaili Medical: -1.18 million, -0.43% of net capital [1] Group 3: Declining Stocks - The stocks with the largest declines included: - Rejing Biological (-5.39%) - Haooubo (-4.67%) - Kehua Biological (-4.25%) - Huitai Medical (-2.79%) - Dabao Medical (-2.04%) [1]
科华生物收盘下跌4.25%,最新市净率0.96,总市值31.32亿元
Sou Hu Cai Jing· 2025-05-12 08:44
Company Overview - Kewah Bioengineering Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic reagents and medical testing instruments [1] - The company's main products include biochemical diagnostics, immunodiagnostics, biochemical immunodiagnostic automation, molecular diagnostics, mass spectrometry, POCT (colloidal gold), and agency services [1] - Kewah has received several honors, including the National Science and Technology Progress Award, recognition as a National High-tech Enterprise, and being a pilot enterprise for national intellectual property [1] Financial Performance - For Q1 2025, Kewah reported revenue of 388 million yuan, a year-on-year decrease of 12.50% [1] - The net profit for the same period was -53.26 million yuan, reflecting a year-on-year decline of 84.79% [1] - The company's gross profit margin stood at 37.39% [1] Market Position - As of the latest data, Kewah's stock closed at 6.09 yuan, down 4.25%, with a price-to-book ratio of 0.96 and a total market capitalization of 3.132 billion yuan [1] - Five institutions hold shares in Kewah, with a total of 114.66 million shares valued at 649 million yuan [1] Industry Comparison - Kewah's PE (TTM) is -4.71, while the industry average is 49.84 [2] - The industry median PE is 36.59, indicating Kewah's significant underperformance compared to peers [2] - The total market capitalization of Kewah is 3.132 billion yuan, which is lower than several competitors in the industry [2]
科华生物收盘上涨9.84%,最新市净率1.00,总市值32.71亿元
Sou Hu Cai Jing· 2025-05-09 08:40
Group 1 - The core viewpoint of the news is that Kehua Bio's stock price has increased by 9.84% to 6.36 yuan, with a market capitalization of 3.271 billion yuan, despite a recent decline in revenue and profit [1] - On May 9, 2023, Kehua Bio experienced a net inflow of main funds amounting to 37.9845 million yuan, indicating a positive trend in fund flow over the past five days, totaling 35.5983 million yuan [1] - Kehua Bio specializes in the research, production, and sales of in vitro diagnostic reagents and medical testing instruments, with key products including biochemical diagnostics, immunodiagnostics, and molecular diagnostics [1] Group 2 - The latest financial report for the first quarter of 2025 shows that Kehua Bio achieved operating revenue of 388 million yuan, a year-on-year decrease of 12.50%, and a net profit loss of approximately 53.26 million yuan, a decline of 84.79% [1] - The company's gross profit margin stands at 37.39% [1] - Kehua Bio holds several honors, including the National Science and Technology Progress Award and recognition as a National High-tech Enterprise [1]
科华生物(002022) - 2025年5月8日投资者关系活动记录表
2025-05-08 10:28
Group 1: Financial Performance and Challenges - The company reported a net profit loss of 2.34 billion in the past year, which increased to 6.41 billion in the current year, indicating a significant financial struggle [4][6]. - The company's overseas business accounts for 23% of its total revenue, with the U.S. market being a minor contributor [3][4]. - The asset-liability ratio stands at 24.22%, with cash reserves of approximately 787 million [4]. Group 2: Strategic Initiatives and Future Plans - The company aims to enhance operational efficiency through lean management and continuous improvement in quality and efficiency [2][3]. - Plans for 2025 include integrating global resources, advancing automation and digitalization, and expanding into diverse overseas markets [5][10]. - The company is committed to ongoing R&D investments to develop comprehensive solutions that meet national health needs [3][5]. Group 3: Market Position and Competitive Landscape - The company has a market coverage of approximately 60% in tertiary hospitals and 40% in blood stations within China [5]. - The company is focusing on enhancing its core products and expanding its market share through strategic marketing and product innovation [5][7]. - The competitive environment has intensified, leading to price reductions in various diagnostic product segments since 2022 [7]. Group 4: Governance and Management Concerns - There are concerns regarding the complexity of financial management due to multiple subsidiaries, which may lead to increased operational costs [6][8]. - The company has established a robust internal control system to ensure compliance and transparency in its operations [4][12]. - The management's compensation has reportedly increased despite the company's financial losses, raising questions about alignment with shareholder interests [6][7].
科华生物2024年净利润暴跌174% 两大业务遭受重挫
Xi Niu Cai Jing· 2025-05-08 01:59
4月29日,科华生物发布年报,2024年实现营业收入17.59亿元,同比下降27.55%;实现归属于上市公司股东的净亏损6.4亿元,同比扩大173.74%;实现扣除 非经常性损益后的净亏损6.69亿元,同比扩大138.82%;基本每股收益为-1.27元/股。 财务结构方面,2024年科华生物毛利率同比下降5.97个百分点至36.79%,主要受集采政策导致产品价格下滑及需求下降影响;净利率降至-41.53%;财务费 用同比激增71.81%,销售及管理费用同比分别下降5.36%和17.76%;经营活动现金流净额为-5011.6万元。 分业务看,2024年科华生物自产产品收入为8.65亿元,同比下降38.9%,占比49.22%;代理产品收入为8.37亿元,同比下降12.86%,占比47.63%。2024年, 科华生物产品出口覆盖100多个国家和地区,完成意大利子公司全资控股,并在越南、巴西等地实现本地化注册销售;累计取得美国FDA、欧盟CE等国际认 证500余项,但年报未披露具体海外收入数据,国际化战略尚处投入期。 2024年,科华生物研发费用同比减少7.8%,但营收占比增加至16.64%,新增KHB Nova 9 ...